Photo: Getty Images North America
President Trump was joined by top drug manufacturing executives in the White House today to announce that the most-favored-nation pricing initiative had officially expanded to 14 of the world’s 17 leading drug manufacturers.
Pfizer, AstraZeneca, Serono, Novo Nordisk, and Lilly had all joined the program, which is meant to keep costs for Medicaid enrollees below those of other high-income nations. They also agreed to donate pharmaceutical ingredients to a national strategic reserve.
Now Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis, and Sanofi have all signed on as well.
President Trump also took time to announce that he’s planning to meet with “the big insurance companies” to try to get them to lower their prices as well, saying they’ve gotten far more money from the American people than they should have.